Dennis C Liotta

USPTO Granted Patents = 125 (Patent Applications = 33)

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 11 (Patent Applications = 23)

Average Co-Inventor Count = 3.4

ph-index = 26

Forward Citations = 1,940(Granted Patents)

Forward Citations (Not Self Cited) = 1,711(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Stone Mountain, GA (US) (1988 - 2008)
McDonough, GA (US) (1995 - 2018)
Atlanta, GA (US) (2003 - 2024)

Company Filing History:

University of Georgia Research Foundation Inc

Imperial College of Science, Technology and Medicine

patents

5. 2 out of 2,202

The United States of America As Represented by the Secretary of

Ortho Pharmaceutical Corporation

patents

9. 1 out of 80

Children's Healthcare of Atlanta, Inc.

patents

10. 1 out of 201

The Florida State University Research Foundation, Inc

patents

11. 1 out of 923

Gilead Sciences, Inc.

patents

12. 1 out of 6

Triangle Pharmaceuticals, Inc.

patents

13. 5 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2025

Loading Chart...

Areas of Expertise:

Progesterone Analogs

N-Methyl-D-Aspartate Receptors

Nucleoside Prodrugs

Neurodegenerative Diseases

Viral Infections

Chemokine Receptor Modulators

Lipid Disulfide Prodrugs

Tricyclic Compounds

Pharmaceutical Compositions

Endocrine Dysfunction

Nmda Receptor Potentiators

Autoimmune Disorders

125 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459970 - Progesterone analogs and uses related thereto (2025-11-04),

2. 12415829 - Progesterone phosphate analogs and uses related thereto (2025-09-16),

3. 12415790 - GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH (2025-09-16),

4. 12414961 - Substituted nucleosides and nucleotides for treating viral infections (2025-09-16),

5. 12398142 - Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases (2025-08-26),

6. 12391664 - GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor (2025-08-19),

7. 12383568 - Lipid disulfide prodrugs and uses related thereto (2025-08-12),

8. 12312328 - Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses (2025-05-27),

9. 12286434 - Pan-tropic entry inhibitors (2025-04-29),

10. 12049474 - Nucleoside prodrugs and uses related thereto (2024-07-30),

11. 12016863 - Inhibitors of RSV replication and applications thereof (2024-06-25),

12. 12006328 - Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto (2024-06-11),

13. 11981652 - GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor (2024-05-14),

14. 11857560 - Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections (2024-01-02),

15. 11801255 - Lipid disulfide prodrugs and uses related thereto (2023-10-31),

Title: The Innovative Journey of Dennis C Liotta

Introduction: Dennis C Liotta, a renowned inventor based in Atlanta, GA (US), has made significant contributions to the field of innovations and patents.

Latest Patents: Dennis C Liotta holds several patents in various industries, showcasing his diverse range of expertise and creativity.

Career Highlights: With a successful career spanning decades, Dennis C Liotta has been a key figure in developing groundbreaking inventions that have revolutionized different sectors.

Collaborations: Throughout his career, Dennis C Liotta has collaborated with leading companies, universities, and research institutions to bring his innovative ideas to life, further solidifying his reputation as a visionary inventor.

Conclusion: Dennis C Liotta's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of inventions and patents, leaving a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.